Immunovant (IMVT)

• Market cap: $3.61B
• 1 day: 4.01%
• 5 days: 6.40%
• 1 month: -9.83%
• 3 months: -19.86%
• 6 months: -34.47%
• Year to date: -15.56%
• 1 year: -41.73%
• 5 years: 38.57%
• 10 years: 113.77%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Employees: 207

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

305% more call options, than puts

Call options by funds: $73.9M | Put options by funds: $18.2M

36% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 28

2% more funds holding

Funds holding: 181 [Q3] → 184 (+3) [Q4]

8% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 61

0.53% more ownership

Funds ownership: 54.06% [Q3] → 54.59% (+0.53%) [Q4]

12% less capital invested

Capital invested by funds: $2.26B [Q3] → $1.98B (-$272M) [Q4]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $44 107% upside
• Avg. target: $46 117% upside
• High target: $51 140% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Yatin Suneja 33% 1-year accuracy 8 / 24 met price target	107% upside $44	Buy Maintained	10 Feb 2025
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 60 / 181 met price target	140% upside $51	Buy Reiterated	10 Feb 2025
B of A Securities Jason Gerberry 50% 1-year accuracy 10 / 20 met price target	112% upside $45	Buy Maintained	15 Jan 2025
Wells Fargo Derek Archila 49% 1-year accuracy 17 / 35 met price target	112% upside $45	Overweight Maintained	19 Dec 2024